News

Kit Delgado, MD, MS Dr. Delgado’s pilot grant will assess physician-level variability in opioid drug prescribing practices for six specific diagnoses across multiple specialties. Dr. Delgrado will use the Optum Cliniformatics DataMart national private insurance claims database to estimate excess prescription opioids prescribed by state and nationally, and calculate the resulting excess cost to the […]

CHERISH director Dr. Bruce Schackman presented at the National Drug Abuse Treatment Clinical Trials Network (CTN) Annual Scientific Meeting on April 12, 2016. The CTN is a NIDA-funded multi-site research project to determine the effectiveness of behavioral, pharmacological, and integrated treatment interventions across a broad range of community-based treatment settings and diversified patient populations. Dr. Schackman’s presentation […]

Dr. Alysse Wurcel is an infectious disease specialist and faculty member at Tufts University School of Medicine with a focus in HIV and hepatitis C (HCV) infection whose research interests closely align with her clinical work. Dr. Wurcel’s research is focused on the treatment of HCV in people who inject drugs (PWID), people in the criminal […]

Dr. McCollister is an Associate Professor and Health Economist in the Department Public Health Sciences at the University Of Miami Miller School Of Medicine. She is the Co-Director of the CHERISH Methodology Core. This interview discusses her interest in substance use health economics and her most recent publication “Cost Effectiveness analysis of a continuing care […]

Karen Lasser, MD, MPH Dr. Lasser’s pilot grant proposes to evaluate economic and health outcomes for a primary care-based HCV treatment program in a patient-centered medical home. The treatment model is based on the chronic care model including a multidisciplinary team with physician, nursing, social worker, pharmacy technician and pharmacist. The team works together to […]

The National Institutes of Health (NIH) recently released an announcement outlining funding priorities for health economics research. The announcement confirms that health economics methods can be instrumental in promoting the NIH mission to improve health and is an integral part of the interdisciplinary science that NIH supports. It goes on to clarify that NIH will prioritize […]

There are more deaths in the US from opioids than from any other unintentional injury–one person died every 30 minutes from an opioid analgesic overdose in the US in 2014. The experience of living with opioid use is harmful both for the opioid user and for his or her spouse. A recent study published in the journal Addiction quantified […]

On December 8th, CHERISH Director Dr. Bruce Schackman, delivered a presentation at the NIDA-funded located at the New York University College of Nursing. CDUHR Co-director and CHERISH Center Advisory Board Member Dr. Sherry Deren welcomed Dr. Schackman, who presented an overview of the mission, goals, and organization of CHERISH. Dr. Schackman highlighted the Methodology Consultation service offered by CHERISH […]

With a price tag of $1,000 per pill and $84,000 for a 12-week course of Sovaldi (sofosbuvir), Gilead Sciences prompted widespread concern about whether its new treatment for hepatitis C (HCV) would bankrupt public and private payers. These concerns were particularly significant for state Medicaid programs, which face both limited state budgets and high HCV […]

The high costs of treating the more than 7 million people with a substance use disorder may be daunting to public and private payers. The costs of not treating them may be even higher, especially if you consider the costs of failing to screen for and treat HIV and hepatitis C in this population. Sorting […]